RLYB (rallybio.com) Net Profit

Corporate emblem and logo of Rallybio Corporation (RLYB)

Monopolistic demand for orphan drugs guarantees Rallybio Corporation (RLYB) long-term superprofits. The company's financial performance, as shaped by GURU.Markets quotes, clearly illustrates this trend, while 0.03 characterizes this valuation parameter. The business advantage is based on exclusive treatments for blood pathologies; however, high research costs and the risk of clinical failures create pressure on capital.

RLYB (rallybio.com) Company Net Income history from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for rallybio.com (RLYB)

- price and consensus price forecast:
Stock Quotes Rallybio|RLYB - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Rallybio Corporation|RLYB - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Rallybio|RLYB - Company Book Value|Market-to-Book Ratio rallybio.com|RLYB - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Rallybio Corporation|RLYB - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Rallybio|RLYB - Company Aggregate Debts|Debts to Book Value Rallybio Corporation|RLYB - Company Long-Term Debt|Company Short-Term Loans and Borrowings Rallybio|Intermediate Coverage Ratio rallybio.com
- net income and valuation multiples indicators:
RLYB - Net Profit
Fundamental valuation:RLYB Rallybio Corp.
Flagship merchandise of Rallybio Corp

For the biotech sector, Rallybio Corporation (RLYB) financial profit reflects the net cash balance after deducting all operating and tax expenses from total income. This indicator's trend allows for an assessment of capital management efficiency and liquidity reserves prior to drug commercialization, turning profit analysis into a tool for monitoring business sustainability in the absence of a stable cash flow.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|Final Profit AQST|scPharma - Net Profit|TECX - Net Profit|Tonix Pharmaceuticals (TNXP) - Company Net Income|SXTC (China SXT Pharmaceuticals, Inc.) - Company Net Income|Company Net Income Eupraxia Pharmaceuticals, Inc.|Company Net Income BHST|Net Income EXOZ (Invizyne Technologies, Inc.)|ORMP - Company Net Income|Net Profit ENTX (Entera Bio)|ipatherapeutics.com - Company Net Income|ABVC BioPharma, Inc. - Net Profit|Net Financial Result Cumberland Pharmaceuticals Inc CPIX|Quantum BioPharma Limited (QNTM) - Company Net Income|Company Net Income FibroGen Corporation (FGEN)|Net Income TELO|RANI: Final Profit|Net Profit SNYR|Net Income lexariabioscience.com LEXX|Company Net Income Pulmatrix Corp PULM|Pheton Holdings Limited (PTHL) - Company Net Income|APM - Company Net Income|Final Profit LYRA (lyratherapeutics.com)|Impact BioMedical Inc (IBO) - Company Net Income|Profit After Tax TNFA (TNF Pharmaceuticals, Inc.)|Company Net Income cbdMD Inc.|Company Net Income PainReform Corp PRFX|Company Net Income Altamira Therapeutics (CYTO)|LIPO (lipella.com) - Final Profit|Net Profit OPTN (OptiNose)|Net Profit Pieris Pharmaceuticals Inc PIRS|PROC: Net Income|Petros Pharma - Profit After Payment of Taxes|QLI: Net Profit|SLRN - Net Financial Result|Company Net Income TFF Pharmaceuticals, Inc.